ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
March 11 2016 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
appointment of Manmeet S. Soni, 38, as executive vice president,
chief financial officer and treasurer, effective March 21, 2016. He
will report to Paris Panayiotopoulos, president and chief executive
officer of ARIAD. Mr. Soni will succeed Edward M. Fitzgerald, who
has made significant contributions to the company as ARIAD’s chief
financial officer since 2002. Mr. Fitzgerald will work closely with
Mr. Soni to ensure a seamless transition.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160311005136/en/
Manmeet S. Soni (Photo: Business
Wire)
“I am delighted that Manmeet will be joining ARIAD as our Chief
Financial Officer,” stated Paris Panayiotopoulos, president and
chief executive officer of ARIAD. “Manmeet brings to ARIAD proven
finance and transaction expertise and will play a critical role in
completing our strategic review to further strengthen our position
as a leading orphan oncology company. We welcome Manmeet to ARIAD
and look forward to working with him.”
Mr. Soni most recently served as Chief Financial Officer of
Pharmacyclics, Inc., a biopharmaceutical company, where he was
responsible for all finance, procurement, information technology
and human resources functions, and where he played a vital role in
the acquisition of Pharmacyclics by AbbVie, Inc. in May 2015.
Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc., where he
served as controller and senior director of finance, and where he
was responsible for accounting, SEC and Treasury functions. Prior
to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers San Jose, in
the Life Science and Venture Capital Group, providing audit and
assurance services to various public and privately held companies
in the pharmaceutical, biotechnology, software and semiconductor
space. Prior to that, he worked at PricewaterhouseCoopers, India
providing audit and assurance services.
“I am very pleased about this opportunity to join the talented
and passionate team at ARIAD, a company focused on making a
difference in the lives of cancer patients with breakthrough
medicines,” said Mr. Soni. “I look forward to working with Paris
and the rest of the team in developing and executing on ARIAD’s
corporate strategy, while concentrating on building long-term value
for shareholders.”
Mr. Panayiotopoulos added, “On behalf of the company’s Board of
Directors, management team and employees, I want to thank Ed for
his tremendous contributions to ARIAD, especially his leadership in
building the financial and operational infrastructure as the
company transitioned from its original focus on research and
development into a fully integrated orphan oncology company.”
Mr. Soni currently serves on the board of Genoscience Pharma. He
graduated from Hansraj College at Delhi University in India. He is
a Certified Public Accountant, licensed in the State of California.
He also completed his Chartered Accountancy from the Institute of
Chartered Accountant of India.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to, the statements made by
Messrs. Panayiotopoulos and Soni, are forward-looking statements
that are based on management's expectations and are subject to
certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These factors, risks and uncertainties include, but are not limited
to, our ongoing strategic review, our ability to successfully
commercialize and generate profits from sales of Iclusig and our
product candidates, if approved; competition from alternative
therapies; our ability to meet anticipated clinical trial
commencement, enrollment and completion dates and regulatory filing
dates for our products and product candidates and to move new
development candidates into the clinic; our ability to execute on
our key corporate initiatives; regulatory developments and safety
issues, including difficulties or delays in obtaining regulatory
and pricing and reimbursement approvals to market our products; our
reliance on the performance of third-party manufacturers and
specialty pharmacies for the supply and distribution of our
products and product candidates; the occurrence of adverse safety
events with our products and product candidates; the costs
associated with our research, development, manufacturing,
commercialization and other activities; the conduct, timing and
results of preclinical and clinical studies of our products and
product candidates, including that preclinical data and early-stage
clinical data may not be replicated in later-stage clinical
studies; the adequacy of our capital resources and the availability
of additional funding; the ability to satisfy our contractual
obligations, including under our leases, convertible debt and
royalty financing agreements; patent protection and third-party
intellectual property claims; litigation; our operations in foreign
countries; risks related to key employees, markets, economic
conditions, health care reform, prices and reimbursement rates; and
other risk factors detailed in our public filings with the U.S.
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160311005136/en/
ARIAD Pharmaceuticals, Inc.For InvestorsMaria Cantor,
617-621-2208Maria.Cantor@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From May 2024 to Jun 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jun 2023 to Jun 2024